USSTOCK.TODAY
Pre-Market
Log in Sign up

Argenx shares plunge 16% on discontinuation of Sjögren's syndrome treatment trial

Investing.com +1 ·

ARGX Argen X SE ADR
$928.44 -0.22%
View chart & analysis →
  1. 1Argenx shares plummeted more than 16% on Thursday.
  2. 2The Independent Data Monitoring Committee recommended stopping the Phase 3 UNITY study based on interim analysis results.
  3. 3Sjögren's syndrome is a chronic inflammatory autoimmune disease with a female-to-male ratio of 9:1.

So what's the key point?

Argenx received a recommendation to stop its treatment trial based on interim results. The stock price fell significantly by more than 16% following this news.

Source Investing.com +1 · View original ↗

Related 3-line summaries

argenx Meets Primary Endpoint in Phase 3 ALKIVIA Trial for Autoimmune Myositis InvestorsHub +1 · Aug 17argenx to acquire Forte Biosciences for $2.2 billion The Wall Street Journal +5 · Jul 27Western Alliance posts Q2 net income of $261.7 million Associated Press +1 · Jul 23
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news